Koers AroCell AB (publ) Nasdaq Stockholm
Aandelen
SE0003883990
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 58,4 mln. 5,39 mln. 5 mln. | Omzet 2025 * | 76,6 mln. 7,06 mln. 6,56 mln. | Marktkapitalisatie | 101 mln. 9,28 mln. 8,62 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -46 mln. -4,24 mln. -3,94 mln. | Nettowinst (verlies) 2025 * | -42 mln. -3,87 mln. -3,6 mln. | EV/omzet 2024 * | 0,99 x |
Nettoliquiditeiten 2024 * | 43 mln. 3,97 mln. 3,68 mln. | Nettoliquiditeiten 2025 * | 40 mln. 3,69 mln. 3,43 mln. | EV/omzet 2025 * | 0,79 x |
K/w-verhouding 2024 * |
-2,19
x | K/w-verhouding 2025 * |
-2,19
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 44,36% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Anders Hultman
CEO | Chief Executive Officer | 50 | 01-12-18 |
Lars Jakobsson
DFI | Director of Finance/CFO | 67 | - |
Gustav Sten
COO | Chief Operating Officer | - | 01-01-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 65 | 01-01-22 | |
Director/Board Member | 63 | 01-05-21 | |
Clas Runnberg
BRD | Director/Board Member | 72 | 01-01-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 44,96 mld. | |
+1,17% | 42,65 mld. | |
+48,77% | 41,85 mld. | |
-4,27% | 29,04 mld. | |
+11,42% | 26,08 mld. | |
-21,39% | 19,03 mld. | |
+4,86% | 12,75 mld. | |
+27,29% | 12,06 mld. | |
-3,50% | 11,75 mld. |